explore -WSS

explore

author：knowledge 2025-09-14 21:35:44 - browse：915

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Study: Hearing aids may slow cognitive decline in those at risk

leisure time

WSS

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

15 die by electrocution after transformer explodes in northern India

Johnson & Johnson sues to stop Medicare negotiation

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Biden administration sends mixed signals on US soldier who crossed into North Korea

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

A single Democrat is willing to weaken Medicare negotiation power

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ER docs worry over extreme heat as a 'mass casualty event'

Walensky prepares to leave CDC — and Congress — behind

Gene therapy for Afghan refugees’ infant will be fully covered

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Study: Hearing aids may slow cognitive decline in those at risk

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Johnson & Johnson sues to stop Medicare negotiation

explore

Why CTE doesn’t keep Americans from enjoying the Super Bowl

A protest over insulin prices is seen as a fight for life

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

A strong 6.5

Lack of darker skin in textbooks, journals harms patients of color

A strong 6.5

hotspot

leisure time

hotspot

entertainment